Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
217P - Impact of VEGF and CD74 expression on response and survival of malignant pleural mesothelioma patients treated with gemcitabine and cisplatin: A phase II retrospective study (ID 565)
12:30 - 13:00 | Author(s): A.S. Saad
Malignant pleural mesothelioma is a fatal and aggressive disease; most patients present with advanced stages. Mesothelioma have one of the highest circulating serum VEGF levels of any solid tumor which is considered as a poor prognostic factor in this disease. Macrophage migration inhibitory factor (MIF) and its receptor CD74 found to be associated with angiogenic activity. Role of MIF has not been shown yet in MPM. This study targets the correlation between expression of VEGF and CD74 (on stored retrospective 44 paraffin embedded mesothelioma specimens) and tumor response to chemotherapy Gemcitabine and platinum combination. The study also figures out the prognostic impact of VEGF and CD74 on the progression free survival (PFS) and overall survival (OS) of the studied patients.
Immunohistochemical staining for VEGF scored from 0 to 3 represent the percentage of cytoplasmic positively stained cells in the tumor. The CD74 expression was recorded in the tumor and the stroma semiquantitatively using the histoscore method with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade. Both CD74 and VEGF immunohistochemical markers were furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression (3).
Combined med/high expression of CD74-TS and VEGF are significantly associated with poor response to gemcitabine and cisplatin chemotherapy (P = 0.03). VEGF expression level did not correlate with PFS (P = 0.09) while high CD74 (T) (P = 0.001) and (S) (P = 0.006) expression significantly impair PFS. Med/high VEGF expression is significantly associated with shorter OS (P = 0.025) whereas, med/high expression of CD74-TS yield a highly significant shorter OS. (P = 0.001).
High expression of VEGF and CD74 T&S are inversely correlated with OS and response to chemotherapy with gemcitabine and cisplatin in Egyptian mesothelioma patients.
Clinical trial identification:
Legal entity responsible for the study:
Clinical Oncology Department Ethical Committe
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.